, Volume 70, Issue 1, pp 351–359 | Cite as

MiR-29b mimics promotes cell apoptosis of smooth muscle cells via targeting on MMP-2

  • Lingguang Shen
  • Yanhui Song
  • Yuqin Fu
  • Peipei Li
Original Article


The phenotypic transformation and dysfunctions of vascular smooth muscle cells (SMCs) such as abnormality proliferation and apoptosis are key pathological basis of atherosclerosis. The recent study aimed to detect the role of miR-29b in phenotypic transformation of SMCs. In this study, we investigated the expression level of miR-29b and MMP-2 in acute coronary syndrome (ACS) patients, verified whether MMP-2 is the target gene of miR-29b by luciferase reporter gene system, and explored the role of miR-29b in the viability and apoptosis of SMCs. We found that the plasma level of miR-29b was significantly downregulated to 56% of controls (p < 0.01). The plasma level of MMP-2 in health controls was 34.9 ± 6.9 ng/mL, and that it significantly increased to 46.2 ± 13.2 ng/mL in ACS patients. MMP-2 is a target gene of miR-29b. The overexpression of miR-29b significantly downregulated the expression of MMP-2 mRNA and protein. miR-29b mimics inhibited the cell viability of SMCs, and cell apoptosis was significantly enhanced compared with the NC group, especially in the early stage. In the presence of MMP-2 inhibitor SB-3CT, the cell viability and apoptosis of SMC cells were significantly reduced and enhanced, respectively, while the miR-29b -inhibited cell viability and -induced cell apoptosis were not significantly changed. Taken together, miR-29b was downregulated in ACS patients. MiR-29 mimics inhibits cell viability and promotes cell apoptosis via directly targeting on MMP-2, which could be a potentially promising therapy target for cardiovascular diseases.


MiR-29b Cell viability Apoptosis Smooth muscle cells MMP-2 


  1. Amin M, Pushpakumar S, Muradashvili N, Kundu S, Tyagi SC, Sen U (2016) Regulation and involvement of matrix metalloproteinases in vascular diseases. Front Biosci (Landmark Ed) 21:89–118CrossRefGoogle Scholar
  2. Arnold N, Koppula PR, Gul R, Luck C, Pulakat L (2014) Regulation of cardiac expression of the diabetic marker microRNA miR-29. PLoS ONE 9:e103284CrossRefGoogle Scholar
  3. Belo VA, Guimaraes DA, Castro MM (2015) Matrix metalloproteinase 2 as a potential mediator of vascular smooth muscle cell migration and chronic vascular remodeling in hypertension. J Vasc Res 52:221–231CrossRefGoogle Scholar
  4. Botham KM, Wheeler-Jones CP (2013) Postprandial lipoproteins and the molecular regulation of vascular homeostasis. Prog Lipid Res 52:446–464CrossRefGoogle Scholar
  5. Chen KC, Wang YS, Hu CY, Chang WC, Liao YC, Dai CY, Juo SH (2011) OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J 25:1718–1728CrossRefGoogle Scholar
  6. Cifani N, Proietta M, Tritapepe L, Di Gioia C, Ferri L, Taurino M, Del Porto F (2015) Stanford-A acute aortic dissection, inflammation, and metalloproteinases: a review. Ann Med 47:441–446CrossRefGoogle Scholar
  7. Dawson K, Wakili R, Ordog B, Clauss S, Chen Y, Iwasaki Y, Voigt N, Qi XY, Sinner MF, Dobrev D, Kaab S, Nattel S (2013) MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 127:1466–1475 (1475e1461-1428) CrossRefGoogle Scholar
  8. Delbosc S, Glorian M, Le Port AS, Bereziat G, Andreani M, Limon I (2008) The benefit of docosahexanoic acid on the migration of vascular smooth muscle cells is partially dependent on Notch regulation of MMP-2/-9. Am J Pathol 172:1430–1440CrossRefGoogle Scholar
  9. Di Pietro N, Formoso G, Pandolfi A (2016) Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. Vascul Pharmacol 84:1–7CrossRefGoogle Scholar
  10. Farr RJ, Joglekar MV, Hardikar AA (2015) Circulating microRNAs in diabetes progression: discovery, validation, and research translation. EXS 106:215–244Google Scholar
  11. Fernandez Machulsky N, Gagliardi J, Fabre B, Miksztowicz V, Lombardo M, Garcia Escudero A, Gigena G, Blanco F, Gelpi RJ, Schreier L, Gidron Y, Berg G (2016) Matrix metalloproteinases and psychosocial factors in acute coronary syndrome patients. Psychoneuroendocrinology 63:102–108CrossRefGoogle Scholar
  12. Ferrans VJ (2002) New insights into the world of matrix metalloproteinases. Circulation 105:405–407Google Scholar
  13. Gabunia K, Herman AB, Ray M, Kelemen SE, England RN, Cadena RD, Foster WJ, Elliott KJ, Eguchi S, Autieri MV (2017) Induction of MiR133a expression by IL-19 targets LDLRAP1 and reduces oxLDL uptake in VSMC. J Mol Cell Cardiol 105:38–48CrossRefGoogle Scholar
  14. Handorf AM, Zhou Y, Halanski MA, Li WJ (2015) Tissue stiffness dictates development, homeostasis, and disease progression. Organogenesis 11:1–15CrossRefGoogle Scholar
  15. Hopps E, Caimi G (2015) Matrix metalloproteases as a pharmacological target in cardiovascular diseases. Eur Rev Med Pharmacol Sci 19:2583–2589Google Scholar
  16. Jiang D, Yang Y and Li D (2017) Lipopolysaccharide induced vascular smooth muscle cells proliferation: A new potential therapeutic target for proliferative vascular diseases. Cell Prolif 50Google Scholar
  17. Kishimoto S, Ishihara M, Takikawa M, Takikawa M, Sumi Y, Nakamura S, Fujita M, Sato T, Kiyosawa T (2014) Three-dimensional culture using human plasma-medium gel with fragmin/protamine microparticles for proliferation of various human cells. Cytotechnology 66:791–802CrossRefGoogle Scholar
  18. Laffont B, Rayner KJ (2017) MicroRNAs in the pathobiology and therapy of atherosclerosis. Can J Cardiol 33:313–324CrossRefGoogle Scholar
  19. Lee J, Lim S, Song BW, Cha MJ, Ham O, Lee SY, Lee C, Park JH, Bae Y, Seo HH, Seung M, Choi E, Hwang KC (2015) MicroRNA-29b inhibits migration and proliferation of vascular smooth muscle cells in neointimal formation. J Cell Biochem 116:598–608CrossRefGoogle Scholar
  20. Leptidis S, El Azzouzi H, Lok SI, de Weger R, Olieslagers S, Kisters N, Silva GJ, Heymans S, Cuppen E, Berezikov E, De Windt LJ, da Costa Martins P (2013) A deep sequencing approach to uncover the miRNOME in the human heart. PLoS ONE 8:e57800CrossRefGoogle Scholar
  21. Ma J, Yang S, Ma A, Pan X, Wang H, Li N, Liu S, Wu M (2017) Expression of miRNA-155 in carotid atherosclerotic plaques of apolipoprotein E knockout (ApoE−/−) mice and the interventional effect of rapamycin. Int Immunopharmacol 46:70–74CrossRefGoogle Scholar
  22. Nielsen LB, Wang C, Sorensen K, Bang-Berthelsen CH, Hansen L, Andersen ML, Hougaard P, Juul A, Zhang CY, Pociot F, Mortensen HB (2012) Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res 2012:896362Google Scholar
  23. Owens GK (2007) Molecular control of vascular smooth muscle cell differentiation and phenotypic plasticity. Novartis Found Symp 283:174–191 (discussion 191–173, 238–141) CrossRefGoogle Scholar
  24. Peng H, Zhong M, Zhao W, Wang C, Zhang J, Liu X, Li Y, Paudel SD, Wang Q, Lou T (2013) Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients. PLoS ONE 8:e82607CrossRefGoogle Scholar
  25. Sobue K, Hayashi K, Nishida W (1999) Expressional regulation of smooth muscle cell-specific genes in association with phenotypic modulation. Mol Cell Biochem 190:105–118CrossRefGoogle Scholar
  26. Tang Y, Urs S, Boucher J, Bernaiche T, Venkatesh D, Spicer DB, Vary CP, Liaw L (2010) Notch and transforming growth factor-beta (TGFbeta) signaling pathways cooperatively regulate vascular smooth muscle cell differentiation. J Biol Chem 285:17556–17563CrossRefGoogle Scholar
  27. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P (1999) Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 353:1547–1557CrossRefGoogle Scholar
  28. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K, Keil U (2000) Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 355:688–700CrossRefGoogle Scholar
  29. Ulrich V, Rotllan N, Araldi E, Luciano A, Skroblin P, Abonnenc M, Perrotta P, Yin X, Bauer A, Leslie KL, Zhang P, Aryal B, Montgomery RL, Thum T, Martin K, Suarez Y, Mayr M, Fernandez-Hernando C, Sessa WC (2016) Chronic miR-29 antagonism promotes favorable plaque remodeling in atherosclerotic mice. EMBO Mol Med 8:643–653CrossRefGoogle Scholar
  30. Viola M, Karousou E, D’Angelo ML, Moretto P, Caon I, Luca G, Passi A, Vigetti D (2016) Extracellular matrix in atherosclerosis: hyaluronan and proteoglycans insights. Curr Med Chem 23:2958–2971CrossRefGoogle Scholar
  31. Zeng Y, Adamson RH, Curry FR, Tarbell JM (2014) Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol Heart Circ Physiol 306:H363–H372CrossRefGoogle Scholar
  32. Zeng Y, Liu XH, Tarbell J, Fu B (2015a) Sphingosine 1-phosphate induced synthesis of glycocalyx on endothelial cells. Exp Cell Res 339:90–95CrossRefGoogle Scholar
  33. Zeng Y, Liu JX, Yan ZP, Yao XH, Liu XH (2015b) Potential microRNA biomarkers for acute ischemic stroke. Int J Mol Med 36:1639–1647CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  • Lingguang Shen
    • 1
  • Yanhui Song
    • 2
  • Yuqin Fu
    • 3
  • Peipei Li
    • 1
  1. 1.Department of Cardiac SurgeryJinan Central Hospital Affiliated to Shandong UniversityJinanChina
  2. 2.Department of Internal MedicineRongFu Military Hospital of JiningJiningChina
  3. 3.Department of Cardiovascular SurgeryJinan Central Hospital Affiliated to Shandong UniversityJinanChina

Personalised recommendations